Rocket Pharmaceuticals, Inc. (RCKT)
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops ex vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red de Enfermedades Raras, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
- Symbol
- RCKT
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $366.96M
- 52 week range
- 2.53 - 5.45
Valuation
- Share price
- $3.02 (close of 2026-09-23)
- P/E (TTM)
- -20.94x
- Price to book
- 0.99x
- Price to free cash flow
- -2.15x
- Enterprise value
- $108.06M
- Book value per share
- $3.37
Price performance
| Period | Change |
|---|
| 1 day | -7.65% |
| 5 days | -11.44% |
| 1 month | -13.96% |
| 3 months | -12.97% |
| 6 months | -30.41% |
| Year to date | -13.96% |
| 1 year | -2.58% |
| 3 years | -85.20% |
| 5 years | -90.85% |
| 10 years | -91.38% |
| All time | -87.42% |
Profitability and growth
- Return on equity
- -80.49%
- Return on invested capital
- -204.73%
- Return on assets
- -67.52%
- Return on capital employed
- -77.19%
- Revenue growth
- 0.00%
- Net income growth
- 13.77%
- Free cash flow growth
- 11.66%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -46.43%
- Current ratio
- 9.24x
- Net debt to EBITDA
- -87.20x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- EBITDA
- $-222.85M
- Net income
- $-223.12M
- Earnings per share
- $-2.01
- Research and development
- $142.01M
- Interest expense
- $1.89M
- Shares outstanding
- 111.12M
Income statement by year
| Period end | Net income | EPS |
|---|
| 2025-12-31 | $-223.12M | $-2.01 |
| 2024-12-31 | $-258.75M | $-2.73 |
| 2023-12-31 | $-245.59M | $-2.92 |
| 2022-12-31 | $-221.86M | $-3.26 |
| 2021-12-31 | $-169.07M | $-2.67 |
| 2020-12-31 | $-139.70M | $-2.52 |
| 2019-12-31 | $-77.27M | $-1.58 |
| 2018-12-31 | $-74.52M | $-1.89 |
| 2017-12-31 | $-19.58M | $-2.88 |
| 2016-12-31 | $-7.57M | $-1.11 |
Margins and returns by year
| Period end | Return on equity | Return on capital |
|---|
| 2025-12-31 | -80.49% | -204.73% |
| 2024-12-31 | -55.86% | -234.65% |
| 2023-12-31 | -49.86% | -235.80% |
| 2022-12-31 | -45.31% | -143.66% |
| 2021-12-31 | -37.18% | -188.71% |
| 2020-12-31 | -27.74% | -315.45% |
| 2019-12-31 | -25.15% | -1360.57% |
| 2018-12-31 | -38.40% | - |
| 2017-12-31 | -126.16% | - |
| 2016-12-31 | -90.47% | - |
Cash and debt by year
| Period end | Cash |
|---|
| 2025-12-31 | $188.90M |
| 2024-12-31 | $372.30M |
| 2023-12-31 | $407.50M |
| 2022-12-31 | $356.39M |
| 2021-12-31 | $388.70M |
| 2020-12-31 | $482.70M |
| 2019-12-31 | $304.10M |
| 2018-12-31 | $213.13M |
| 2017-12-31 | $100.01M |
| 2016-12-31 | $126.47M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $-190.45M | $37.06M |
| 2024-12-31 | $-215.59M | $43.92M |
| 2023-12-31 | $-211.35M | $39.41M |
| 2022-12-31 | $-186.50M | $31.01M |
| 2021-12-31 | $-128.78M | $29.24M |
| 2020-12-31 | $-95.25M | $18.57M |
| 2019-12-31 | $-87.93M | $13.37M |
| 2018-12-31 | $-55.24M | $13.60M |
| 2017-12-31 | $-16.72M | $1.32M |
| 2016-12-31 | $-5.84M | $274.00K |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-05
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-06 | Jun/2026 | $0.28 |
| 2026-05-07 | - | - |
| 2026-02-26 | - | - |
| 2025-11-06 | - | - |
| 2025-08-07 | - | - |
| 2025-05-08 | - | - |
| 2025-02-27 | - | - |
| 2024-11-07 | - | - |
Filings and sources
- Company website
- rocketpharma.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades